Survodutide (5mg/10mg)

What is Survodutide?

Survodutide, also called BI 456906, is a peptide studied at GLP-1 and glucagon receptors. This catalog offers 5mg and 10mg research vials. It is a dual agonist, not a GIP/GLP-1 compound.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

The GLP-1 and glucagon receptor arms allow researchers to examine two distinct metabolic signals. Cell-based assays measure receptor activation, while animal studies examine whole-organism responses. These measurements are not interchangeable.

What are the research questions?

• GLP-1 and glucagon receptor activity
• Comparing receptor activity across species
• Connecting cellular assays with preclinical metabolic endpoints

What does the published work describe?

The 2022 discovery paper reports receptor pharmacology and preclinical experiments for BI 456906. The work includes cell assays and animal models. It establishes a research context for the molecule, not a promise of clinical benefit or verification of this inventory.

Experimental models in the cited papers

• Cell-based receptor assays
• Diet-induced obese animal models

What could future research explore?

Matched receptor assays can investigate which signals contribute to an observed response. Potential metabolic and liver-related applications require formulation-specific studies and cannot be inferred from receptor names alone.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Preclinical findings are model-dependent and do not establish human effectiveness or safety. The cited material must match the supplied construct before results can be meaningfully compared. Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Zimmermann T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022. PMID 36356832

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Survodutide handled in the lab?

Plan a Survodutide stock solution from the sequence, the listed molecular weight (4493.10 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave